Drug Research
Drug Discovery & Development

Ethypharm agrees to acquire UK-based Martindale Pharma

Published 20 January 2017

Ethypharm has agreed to acquire Martindale Pharma, a UK-based specialty pharmaceutical firm offering essential medicines to more than 50 countries across the world.

The company specializes in the field of opioid addiction, emergency care and sterile injectables.

By joining forces with Martindale Pharma, Ethypharm reinforces its presence in the UK. The combined group will also benefit from a broader geographical reach and strengthen its manufacturing capabilities including solid dose, injectables and oral liquids.

The combination of the two companies will create a group with revenues of more than €300 million and a solid platform for future growth.

Martindale Pharma CEO and future Chief Operating Officer of Ethypharm Michael Harris said: "The combination of Ethypharm and Martindale enables us to create a leading company in the fields of emergency care, pain and addiction. It allows us to take our products into many other markets helping patients around the world get access to better medicines."

Ethypharm CEO Hugues Lecat said: "I am delighted to welcome the Martindale Pharma team within Ethypharm. The combined group will benefit from Martindale's expertise and talents to accelerate its international growth."



Source: Company Press Release